| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer
|
Chih-Hsin Yang;Lin C.-B;Lee K.-H;Cho E.K;Park K;Tanaka H;Ichinose Y;Yamada K;Kato T;Kaneda H;Hayashi H;Nakagawa K;Yoh K;Hida T;Oshita F;Yoshioka H;Hara K;Asato T;Kubota K; Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non?�Small-Cell Lung Cancer
|
Park K.;Puri T;Orlando M;Han B;Mok T;Chih-Hsin Yang; CHIH-HSIN YANG; Mok T; Han B; Orlando M; Puri T; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
|
Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos
|
Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ?�real-world??clinical setting
|
Park K;Wan-Teck Lim D;Okamoto I;Chih-Hsin Yang; Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Shaw A.T.; Passos V.Q.; Chen Z.; Viraswami-Appanna K.; Spigel D.R.; Scagliotti G.V.; Mok T.; Su W.-C.; Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Nishio M.;Felip E.;Orlov S.;Park K.;Chong-Jen Yu;Tsai C.-M.;Cobo M.;Mckeage M.;Su W.-C.;Mok T.;Scagliotti G.V.;Spigel D.R.;Viraswami-Appanna K.;Chen Z.;Passos V.Q.;Shaw A.T. |
| 國立成功大學 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio, M.;Felip, E.;Orlov, S.;Park, K.;Yu, C.-J.;Tsai, C.-M.;Cobo, M.;McKeage, McKeage M.;Su, W.-C.;Mok, T.;Scagliotti, G.V.;Spigel, D.R.;Viraswami-Appanna, K.;Chen, Z.;Passos, V.Q.;Shaw, A.T. |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 國立成功大學 |
2018 |
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
|
Gerber, D.E.;Horn, L.;Boyer, M.;Sanborn, R.;Natale, R.;Palmero, R.;Bidoli, P.;Bondarenko, I.;Germonpre, P.;Ghizdavescu, D.;Kotsakis, A.;Lena, H.;Losonczy, G.;Park, K.;Su, W.-C.;Tang, M.;Lai, J.;Kallinteris, N.L.;Shan, J.S.;Reck, M.;Spigel, D.R. |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 臺北醫學大學 |
2008 |
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
|
Chang MH;Ahn JS; Lee J; Kim KH; Park YH; Han J;Ahn MJ;Park K |
